Grace Therapeutics (GRCE) Payables (2017 - 2026)

Grace Therapeutics has disclosed Payables across 10 years of filings, most recently posting $1.2 million for Q2 2026.

• In Q2 2026, Payables fell 46.0% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $1.2 million (down 46.0% YoY), while the FY2026 annual figure was $2.1 million, up 11.19% from the prior year.
• Payables came in at $1.2 million for Q2 2026 at Grace Therapeutics, down from $2.1 million in the prior quarter.
• In the past five years, Payables ranged from a high of $3.7 million in Q3 2022 to a low of $1.2 million in Q3 2025.
• Average Payables over 5 years is $2.3 million, with a median of $2.1 million recorded in 2024.
• Year-over-year, Payables soared 111.39% in 2022 and plunged 63.83% in 2023.
• Over 5 years, Payables stood at $3.4 million in 2022, then tumbled by 48.04% to $1.7 million in 2023, then grew by 12.89% to $2.0 million in 2024, then sank by 34.86% to $1.3 million in 2025, then slipped by 2.65% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $1.2 million in Q2 2026, $2.1 million in Q1 2026, and $1.3 million in Q4 2025.